References
- Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463–516.
- Sang QX, Jin Y, Newcomer RG, Monroe SC, Fang X, Hurst DR et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 2006;6:289–316.
- Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–174.
- Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657–672.
- Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480–498.
- Katsuno H, Shirakawa R, Miyazaki K, Ozeki Y, Yasumitsu H. Production of active MMP7 in E. coli and its application for metalloproteinase inhibitors screening. Protein Pept Lett 2010;17:568–572.
- Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–2503.
- Saarialho-Kere UK, Chang ES, Welgus HG, Parks WC. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest 1992;90:1952–1957.
- Grant GA, Eisen AZ, Marmer BL, Roswit WT, Goldberg GI. The activation of human skin fibroblast procollagenase. Sequence identification of the major conversion products. J Biol Chem 1987;262:5886–5889.
- Murphy G, Allan JA, Willenbrock F, Cockett MI, O’Connell JP, Docherty AJ. The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem 1992;267:9612–9618.
- Cockett MI, Bebbington CR, Yarranton GT. The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines. Nucleic Acids Res 1991;19:319–325.
- Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987;248:265–268.
- Rosenfeld SA, Ross OH, Hillman MC, Corman JI, Dowling RL. Production and purification of human fibroblast collagenase (MMP-1) expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif 1996;7:423–430.
- Iyer S, Wei S, Brew K, Acharya KR. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1. J Biol Chem 2007;282:364–371.
- Chung L, Shimokawa K, Dinakarpandian D, Grams F, Fields GB, Nagase H. Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem 2000;275:29610–29617.
- Gehring MR, Condon B, Margosiak SA, Kan CC. Characterization of the Phe-81 and Val-82 human fibroblast collagenase catalytic domain purified from Escherichia coli. J Biol Chem 1995;270:22507–22513.
- Chang TL. Inhibitory effect of flavonoids on 26S proteasome activity. J Agric Food Chem 2009;57:9706–9715.
- Ou L, Ma J, Zheng X, Chen X, Li G, Wu H. The expression and refolding of isotopically labeled recombinant Matrilysin for NMR studies. Protein Expr Purif 2006;47:367–373.
- Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV et al. Discovery of potent, achiral matrix metalloproteinase inhibitors. J Med Chem 1998;41:3568–3571.
- Covington MD, Burghardt RC, Parrish AR. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 2006;290:F43–F51.
- Shen SC, Ko CH, Tseng SW, Tsai SH, Chen YC. Structurally related antitumor effects of flavanones in vitroand in vivo: involvement of caspase 3 activation, p21 gene expression, and reactive oxygen species production. Toxicol Appl Pharmacol 2004;197:84–95.
- Ko CH, Shen SC, Lee TJ, Chen YC. Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 2005;4:281–290.
- Ende C, Gebhardt R. Inhibition of matrix metalloproteinase-2 and -9 activities by selected flavonoids. Planta Med 2004;70:1006–1008.
- Ye QZ, Hupe D, Johnson L. Catalytic domains of matrix metalloproteinases: a molecular biology approach to drug discovery. Curr Med Chem 1996;3:407–418.